Prescription drug · ANDA
Cilostazol NDC 70436-157
Cilostazol 100 mg/1 · Tablet · Oral · Slate Run Pharmaceuticals, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70436-157-06 | 70436015706 | 60 TABLET in 1 BOTTLE (70436-157-06)Marketed from Apr 16, 2021 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Cilostazol
- Generic name (nonproprietary)
- cilostazol
- Active ingredients
- Cilostazol — 100 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 077208
- Marketing start
- Listing expires
- Other FDA classes
- Phosphodiesterase 3 Inhibitors (Mechanism)
- Identifiers
- Product ID 70436-157_45be0b2e-7ae1-42d2-e063-6394a90a1da6SPL ID 45be0b2e-7ae1-42d2-e063-6394a90a1da6SPL set ID db0278e9-4ece-4aaf-9216-6bcbec58206aRxCUI 242461, 242462UNII N7Z035406BUPC 0370436156061, 0370436157068
- Pharmacologic class
- Phosphodiesterase 3 Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N470436015706followed by a unit qualifier and the quantityPackage 70436-0157-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. Cilostazol tablets are a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance (1)
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 077208
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Cilostazol | Cilostazol 50 mg/1 | TabletOral | Slate Run Pharmaceuticals, LLC | 70436-156 |